Medical Affairs, Osteoporosis Franchise, Sandoz China, Tianjin, China.
Medical Affairs, Osteoporosis Franchise, Sandoz China, Chengdu, China.
Orthop Surg. 2019 Aug;11(4):569-577. doi: 10.1111/os.12476. Epub 2019 Jul 19.
To investigate the knowledge and practices of Chinese doctors in the management of osteoporotic fractures after the Chinese osteoporotic fracture guidelines update and aseries of medical education in 2017.
This was a cross-sectional survey of doctors in 71 cities across Mainland China. Based on the 2017 Chinese guidelines for the diagnosis and treatment of osteoporotic fractures, a questionnaire was designed and pre-tested for reliability and validity. Doctors were surveyed with the questionnaire after scientific meetings during February 2017 to January 2018 through WeChat or conference digital platforms or in paper form. Descriptive statistics was used to analyze the responses to the questionnaire.
Overall, 314 valid questionnaires were confirmed. Regarding diagnosis, 77% agreed that osteoporosis could be diagnosed once an osteoporotic fracture occurred; 83% believed that the bone mineral density criteria for osteoporosis diagnosis would be T ≤ -2.5 SD. For treatment, almost all (99.7%) agreed with anti-osteoporosis treatment being one of the basic principles of osteoporotic fracture treatment; 71.6% considered bisphosphonates as the most commonly used anti-osteoporosis drug; 97% believed that patients who have used anti-osteoporosis drugs should reassess osteoporosis after osteoporotic fractures instead of discontinue; 95% thought that the patients who did not use anti-osteoporosis medications before osteoporotic fracture should be treated with anti-osteoporosis drugs after fracture treatment as early as possible; 89% agreed that the standard use of bisphosphonates after osteoporotic fracture would not affect bone healing adversely; 59% believed the course of bisphosphonates treatment for osteoporosis would be 3-5 years, and 27% considered it to be 1-3 years. The patient follow-up rate was poor: 46% selected follow-up rate <30%; only 20% selected follow-up rate >50%. Only 31% of the hospitals had long-term management programs for osteoporotic fractures.
Doctors generally adhered to the updated Chinese guidelines for osteoporotic fractures; frequent participation in medical education can help doctors to increase their awareness of osteoporosis as well as their acceptance and practice of the guidelines.
调查中国医生在 2017 年中国骨质疏松性骨折诊治指南更新和一系列医学教育后，对骨质疏松性骨折管理的知识和实践情况。
这是一项对中国大陆 71 个城市医生的横断面调查。根据 2017 年中国骨质疏松性骨折诊治指南，设计了一份问卷，并进行了可靠性和有效性的预测试。2017 年 2 月至 2018 年 1 月，通过微信或会议数字平台或纸质形式，在科学会议期间对医生进行问卷调查。采用描述性统计方法分析问卷的应答情况。
共确认 314 份有效问卷。在诊断方面，77%的医生同意一旦发生骨质疏松性骨折即可诊断骨质疏松症；83%的医生认为骨质疏松症诊断的骨密度标准为 T≤-2.5 SD。在治疗方面，几乎所有（99.7%）的医生同意抗骨质疏松治疗是骨质疏松性骨折治疗的基本原则之一；71.6%的医生认为双膦酸盐类药物是最常用的抗骨质疏松药物；97%的医生认为骨质疏松性骨折患者在发生骨质疏松性骨折后应重新评估骨质疏松症，而不是停止抗骨质疏松治疗；95%的医生认为骨质疏松性骨折前未使用抗骨质疏松药物的患者应在骨折治疗后尽早开始抗骨质疏松治疗；89%的医生认为骨质疏松性骨折后标准使用双膦酸盐类药物不会对骨愈合产生不利影响；59%的医生认为骨质疏松症双膦酸盐类药物治疗疗程为 3-5 年，27%的医生认为疗程为 1-3 年。患者随访率较差：46%的医生选择随访率<30%；只有 20%的医生选择随访率>50%。只有 31%的医院有骨质疏松性骨折的长期管理方案。
医生普遍遵循更新后的中国骨质疏松性骨折诊治指南；频繁参加医学教育有助于提高医生对骨质疏松症的认识，以及对指南的接受和实践。
